On June 25, 2018, the U.S. Food & Drug Administration (FDA) approved EPIDIOLEX®, a CBD oral solution for the treatment of seizures associated with two epilepsy syndromes – Lennox-Gastaut syndrome and Dravet syndrome. Epidiolex represents a new medication option for children with these types of epilepsy. It is also the first ever FDA approved medication to treat seizures in Dravet syndrome.
In May 2018, the New England Journal of Medicine reported the following results from Gold Standard Studies of Epediolex: The addition of CBD to a traditional seizure medication significantly decreased the frequency of seizures in adults and children suffering from Lennox-Gastaut Syndrome. In May 2017, the New England Journal of Medicine also reported that people suffering from Dravet Syndrome experienced a noticeable decrease in convulsive seizures than those who were taking a placebo.